Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Ipsen Group
Femme et Homme Max 99 ans
Ipsen Group, SCRAS Institut Henri Beaufour
MAJ Il y a 4 ans
A Phase II, Randomised, Double-Blind Study to Compare the Safety and Efficacy of One Treatment Cycle of Clostridium Botulinum Type A Toxin (50 Units) When Reconstituted from Either a 125 Unit or a 500 Unit Presentation for the Treatment of Glabellar Lines
The main objective is the assessment of the relative clinical safety of the two different presentations (125 U vial (referred to as Reloxin) and 500 U vial (Dysport®)) by comparison of the incidence a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ipsen Group
MAJ Il y a 4 ans
A clinical trial to determine the maximum dose, safety and tolerability of one injection of lanreotide prolonged release formulation in patients with acromegaly previously treated with either octreotide LAR or lanreotide Autogel
To identify the maximum tolerated dose (MTD) and to investigate the pharmacokinetics (PK) of a single dose of lanreotide PRF in subjects with acromegaly
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations